Welcome to our dedicated page for Dynavax Technolo SEC filings (Ticker: DVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dynavax Technologies Corporation (DVAX) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as a Nasdaq Global Select Market issuer. Dynavax uses these filings to report financial results, clinical milestones and significant corporate events related to its vaccines business, including HEPLISAV-B®, CpG 1018® adjuvant and its pipeline of adjuvanted vaccine candidates.
Among the most frequently referenced documents are Form 8-K current reports. Dynavax files 8-Ks to furnish quarterly financial results, such as the second and third quarter 2025 earnings releases, under Item 2.02 (Results of Operations and Financial Condition). These filings typically attach press releases that detail HEPLISAV-B net product revenue, total revenues, research and development spending, selling, general and administrative expenses, and adjusted EBITDA, along with management commentary and updated guidance.
Dynavax also uses Form 8-K to disclose clinical and pipeline developments and corporate governance changes. For example, an August 21, 2025 8-K furnished a press release and corporate presentation on topline Phase 1/2 results for Z-1018, the company’s shingles vaccine candidate. Another 8-K dated October 15, 2025 described changes in senior management roles, including transitions in the positions of President, Chief Operating Officer and Chief Medical Officer.
In addition, Dynavax’s filings include information on its capital markets activities, such as share repurchase programs and other financial measures, and will incorporate documents related to significant transactions. The announced agreement for Sanofi to acquire Dynavax through a cash tender offer and subsequent merger is expected to generate tender offer materials on Schedule TO and a Solicitation/Recommendation Statement on Schedule 14D-9, as described in the companies’ joint press release.
On Stock Titan, users can review Dynavax’s SEC filings as they are made available from EDGAR and access AI-powered summaries that explain the key points of lengthy documents like earnings releases and transaction-related filings. This includes highlighting items such as quarterly performance trends, updates on vaccine programs like HEPLISAV-B and Z-1018, and the implications of corporate events. The page also surfaces filings related to executive changes and other material events so that investors can quickly understand what Dynavax has reported to regulators.
Sanofi, through Samba Merger Sub, has successfully completed its cash tender offer for Dynavax Technologies at $15.50 per share. The purchaser has irrevocably accepted for payment all Dynavax shares validly tendered and not withdrawn under the offer.
Because the Sanofi group now holds more than the percentage of shares needed to approve the merger agreement, it plans to complete a merger under Section 251(h) of Delaware law without a Dynavax stockholder vote. At the merger’s effective time, each remaining Dynavax share (with limited exceptions such as treasury shares and properly perfected appraisal shares) will be converted into the right to receive the same $15.50 cash merger consideration. After the merger, Dynavax shares will be delisted from the NASDAQ Global Select Market and deregistered under the Exchange Act, ending public trading in the stock.
Dynavax Technologies Corporation filed an amendment to its Schedule 14D-9 relating to the all-cash tender offer by Sanofi’s subsidiary to acquire all Dynavax shares for $15.50 per share. The update corrects a disclosure about fees paid to Goldman Sachs.
The revised statement now says that during the two-year period ended December 23, 2025, Goldman Sachs recognized approximately $6 million in compensation for financial advisory and/or underwriting services to Dynavax and its affiliates, correcting a prior figure of approximately $11 million. All other information in the Schedule 14D-9 remains unchanged.
Dynavax Technologies filed an amendment to its Schedule 14D-9 related to the pending tender offer by Sanofi’s indirect subsidiary, Samba Merger Sub, to acquire all Dynavax shares for $15.50 per share in cash.
The amendment updates regulatory disclosures for Germany. It states that Germany’s Federal Ministry for Economic Affairs and Energy (BMWK) has cleared the acquisition of 100% of the voting rights in Dynavax GmbH by the Sanofi subsidiary under German foreign direct investment laws, effective January 29, 2026. This clearance satisfies a key German foreign investment review condition for the transaction.
Sanofi, through Samba Merger Sub, is pursuing a cash tender offer to acquire all outstanding shares of Dynavax Technologies for $15.50 per share. This amendment reports that Germany’s Federal Ministry for Economic Affairs and Energy cleared the related Dynavax GmbH foreign investment transaction effective January 29, 2026.
The German foreign direct investment clearance had been a condition to acquiring 100% of the voting rights in Dynavax GmbH, a Dynavax subsidiary. With this regulatory approval in place, a key international review hurdle tied to the tender offer structure has been satisfied.
Dynavax Technologies Corporation filed Amendment No. 1 to its Schedule 14D-9 to supplement its earlier solicitation/recommendation statement in connection with the unsolicited tender offer by Samba Merger Sub (an indirect wholly owned subsidiary of Sanofi) to acquire all outstanding common shares for $15.50 per share. The amendment states that, as of
Samba Merger Sub, an indirect Sanofi subsidiary, has amended its cash tender offer for all Dynavax Technologies shares at $15.50 per share. The update confirms key regulatory clearances and outlines shareholder litigation related to the deal.
The 15-day waiting period under the U.S. Hart-Scott-Rodino Act expired effective January 27, 2026, satisfying the offer condition tied to U.S. antitrust review. German merger control clearance was also received from the Federal Cartel Office on January 14, 2026, allowing the acquisition to proceed under German competition law.
As of January 28, 2026, one federal and two New York state court complaints, plus multiple stockholder demand letters and a books and records demand, challenge aspects of the transaction disclosures and seek to delay or unwind the deal. Dynavax and its directors state they intend to vigorously defend these actions.
Dynavax Technologies Corp. insider activity: President & COO David F. Novack reported multiple equity transactions dated January 15, 2026. He exercised stock options to acquire 20,000 common shares at $6.805 per share and 94,000 common shares at $10.47 per share. On the same date, he sold 114,000 common shares at a weighted average price of $15.64, leaving him with 63,344 common shares held directly after the transactions. The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 6, 2024, and notes that the sale price reflects trades executed between $15.585 and $15.665. Certain stock options involved in the exercises are described as fully vested.
A holder of common stock in DVAX has filed a notice of proposed sale under Rule 144. The filing covers a planned sale of 114,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an indicated aggregate market value of $1,782,726.80. These shares were acquired from the issuer on the same day through a stock option exercise paid in cash.
The notice also reports that the same seller, identified as David Novack, sold 30,000 common shares on 12/24/2025 for gross proceeds of $464,700.00. The issuer had 117,424,968 common shares outstanding at the time indicated, providing context for the size of the planned sale.
Dynavax Technologies Corporation has received an all-cash tender offer from Samba Merger Sub, an indirect wholly owned subsidiary of Sanofi, to buy any and all outstanding Dynavax common shares for $15.50 per share. The offer is part of a merger agreement under which Dynavax will become a wholly owned subsidiary of Sanofi and its stock will cease to be publicly traded, using a Section 251(h) short-form merger after a successful tender.
The deal is subject to a majority of shares being validly tendered, expiration or termination of required antitrust waiting periods, absence of legal blocks, continued accuracy of Dynavax’s representations, covenant compliance, and no continuing material adverse effect. Dynavax’s board unanimously determined the transaction is fair and in the best interests of stockholders and recommends that stockholders accept the offer and tender their shares.
At closing, stock options, RSUs and PSUs generally convert into cash based on the $15.50 merger consideration (with certain 2025–2026 awards converted into deferred cash-based awards), and change-in-control severance and 280G tax mitigation features, including potential excise tax Make-Whole Payments capped at $10 million in aggregate, provide additional benefits to executives. Directors and officers will receive the same per-share price as other holders for their common shares.
Dynavax Technologies (DVAX) reported Q3 results with total revenue of $94.9 million, led by HEPLISAV-B product revenue of $90.0 million. Net income for the quarter was $26.9 million, up from $17.6 million a year ago, as higher product sales offset operating costs.
Year-to-date, revenue reached $258.5 million. Despite stronger sales, the company recorded a year-to-date net loss of $50.5 million, driven primarily by an $82.1 million loss on debt extinguishment related to a March 2025 refinancing of its convertible notes. Other revenue included $4.7 million in Q3 from the U.S. Department of Defense collaboration.
Liquidity remained solid. Cash and cash equivalents were $160.2 million and marketable securities were $487.6 million as of September 30, 2025. Total assets were $946.5 million and stockholders’ equity was $534.1 million. The company completed its $200 million share repurchase authorization, reducing common shares outstanding; as of November 3, 2025, there were 117,424,968 shares outstanding.
Dynavax refinanced a portion of its convertibles, issuing $225.0 million of 2.00% notes due 2030 and leaving $40.2 million of 2.50% notes due 2026 outstanding. Q3 diluted EPS was $0.21.